Company news
Fortress Biotech, Inc. news in 2022
Fortress Biotech, Inc.'s news releases, calls and decks from 2022, newest first.
Fortress Biotech Appoints Lucy Lu, M.D., to its Board of Directors
December 18, 2022
Fortress Biotech Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights
November 13, 2022
Fortress Biotech Announces Timing of Regular Monthly Dividend for October, November and December 2022 for its 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock
October 4, 2022
Fortress Biotech Reports Second Quarter 2022 Financial Results and Recent Corporate Highlights
August 10, 2022
Fortress Biotech Appoints David Jin as Chief Financial Officer
July 21, 2022
Fortress Biotech Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating Dotinurad for the Treatment of Gout in the United States
May 30, 2022
Fortress Biotech Reports First Quarter 2022 Financial Results and Recent Corporate Highlights
May 11, 2022
Fortress Biotech Announces Virtual Two-Day R&D Summit Hosted by B. Riley Securities on Tuesday, April 5 and Wednesday, April 6, 2022
March 31, 2022
Fortress Biotech Reports Record 2021 Financial Results and Recent Corporate Highlights
March 27, 2022
Fortress Biotech, Cyprium Therapeutics and Sentynl Therapeutics Announce CUTX-101, Copper Histidinate, Data to be Presented at 2022 American College of Medical Genetics Annual Clinical Genetics Meeting
March 20, 2022
Fortress Biotech Announces Virtual Two-Day Corporate Access Summit Hosted by B. Riley Securities on Tuesday, April 5 and Wednesday, April 6, 2022
March 2, 2022